Stay updated on Pembrolizumab vs. Liver-Directed Therapy in NET Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs. Liver-Directed Therapy in NET Clinical Trial page.

Latest updates to the Pembrolizumab vs. Liver-Directed Therapy in NET Clinical Trial page
- Check5 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed. Notably, the information regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference0.8%
- Check12 days agoNo Change Detected
- Check20 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.6%
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check41 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1.0%
- Check48 days agoChange DetectedThe page has removed specific studies related to Pembrolizumab and its application in treating neuroendocrine tumors and liver metastases.SummaryDifference0.2%
- Check70 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab vs. Liver-Directed Therapy in NET Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs. Liver-Directed Therapy in NET Clinical Trial page.